Compound News and Research

RSS

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Study: Cigarette smoking, fructose consumption can worsen NAFLD

Recent studies suggest that modifiable risk factors such as cigarette smoking and fructose consumption can worsen nonalcoholic fatty liver disease. With NAFLD, fat accumulates in the liver of overweight individuals despite drinking little alcohol, causing in some cases liver scarring that can lead to liver failure.

27 Apr 2010

PPD confirms Japanese approval for Takeda's NESINA NDA

PPD, Inc. today confirmed that Takeda Pharmaceutical Company Limited's new drug application for NESINA® (alogliptin), a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare on April 16. PPD's compound partnering division collaborated with Takeda to develop this product.

27 Apr 2010

PPD reports 30% sequential increase in gross authorizations for first-quarter 2010

PPD, Inc. today reported its financial and operating results for the first quarter ended March 31, 2010.

27 Apr 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.

27 Apr 2010

SuperGen's total revenues for 2010 first-quarter increased to $14.4M

SuperGen, Inc. today reported financial results for the first quarter ended March 31, 2010.

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

The Frost Group agrees to make investment in ChromaDex

ChromaDex Corporation, a natural products chemistry company which provides novel and innovative ingredients to the dietary supplement, food, beverage and cosmetic markets, announced today The Frost Group, LLC, led by Miami entrepreneur and billionaire Dr. Phillip Frost, has agreed to make an investment in ChromaDex.

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Researchers synthesize metal compounds that can be effective in treatment of cancer

Scientists from Bochum have managed to accurately determine the location of metal complexes within living cancer cells using Raman microscopy. The researchers have thus gained new insights into the mechanism of action of metal-containing drugs, to which they ascribe great potential capacities, e.g. in the treatment of cancer.

26 Apr 2010

Enhancing residence time improves drug effectivity: Study

Studies led by Stony Brook University professor of chemistry Peter J. Tonge indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents.

26 Apr 2010

Recent business progress at Penwest Pharmaceuticals

Penwest Pharmaceuticals Co. today sent a letter to its shareholders to provide an update on the Company's recent progress and on corporate governance developments.

24 Apr 2010

NPAF urges Colorado Governor to exercise line item veto of $17.9M reduction in 2011 Medicaid program

The National Patient Advocate Foundation, a national, non-profit organization dedicated to the mission of creating avenues of improved patient access to health care through public policy reform at the state and federal levels, delivered a letter to Colorado Governor Bill Ritter, urging him to exercise a line item veto of a $17.9 million reduction in Medicaid funding passed recently by the Colorado legislature as part of the fiscal year 2011 budget.

24 Apr 2010

Expected impact of recently enacted U.S. Health Care Reform legislation

Merck & Co., Inc. today provided information on the expected impact of the recently enacted U.S. Health Care Reform legislation.

24 Apr 2010

GIS scientists' zebrafish model may aid drug development for PD

Scientists at the Genome Institute of Singapore, a biomedical research institute of the Agency for Science, Technology and Research, have recently developed a zebrafish model for Parkinson's disease that can be used for understanding the mechanism underlying its development. The knowledge gained will be helpful for future screening of new drugs to treat Parkinson's disease.

23 Apr 2010

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted it patent number GB2460597 titled "N,N-Disubstituted aminoalkylBiPhenyl Antagonists OF Prostaglandin d2 RECEPTORS."

23 Apr 2010

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

Compound News and Research

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Study: Cigarette smoking, fructose consumption can worsen NAFLD

PPD confirms Japanese approval for Takeda's NESINA NDA

PPD reports 30% sequential increase in gross authorizations for first-quarter 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

SuperGen's total revenues for 2010 first-quarter increased to $14.4M

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

The Frost Group agrees to make investment in ChromaDex

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Researchers synthesize metal compounds that can be effective in treatment of cancer

Enhancing residence time improves drug effectivity: Study

Recent business progress at Penwest Pharmaceuticals

NPAF urges Colorado Governor to exercise line item veto of $17.9M reduction in 2011 Medicaid program

Expected impact of recently enacted U.S. Health Care Reform legislation

GIS scientists' zebrafish model may aid drug development for PD

Amira Pharmaceuticals granted UK patent covering novel small molecule inhibitors of DP2 receptor

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News